Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Price, News & Analysis

TCR2 Therapeutics logo

About TCR2 Therapeutics Stock (NASDAQ:TCRR)

Key Stats

Today's Range
$1.48
$1.63
50-Day Range
$1.48
$1.98
52-Week Range
$0.82
$3.88
Volume
3.91 million shs
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

Poseida Therapeutics Inc Ordinary Shares PSTX
DICE Therapeutics Inc.
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Recap: TCR2 Therapeutics Q1 Earnings
10-Q: TCR2 THERAPEUTICS INC.
See More Headlines

TCRR Stock Analysis - Frequently Asked Questions

TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.06.

TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Block (SQ), Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
11/10/2021
Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

Net Income
$-151,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:TCRR) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners